{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:06:43Z","timestamp":1790845603905,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04451-4","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T14:46:12Z","timestamp":1764168372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A novel scoring system to identify patients at low risk for hepatocellular carcinoma five years after DAA-Induced sustained virological response: a retrospective cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Hideki","family":"Fujii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhide","family":"Mitsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Seko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihisa","family":"Moriguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seita","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiyu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Takami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanji","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"4451_CR1","unstructured":"WHO. (2024): Hepatitis C. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed 9 Jan 2025."},{"key":"4451_CR2","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1017\/S0950268814000478","volume":"142","author":"H Toyoda","year":"2014","unstructured":"Toyoda H, Kumada T, Takaguchi K, Shimada N, Tanaka J. Changes in hepatitis C virus genotype distribution in Japan. Epidemiol Infect. 2014;142:2624\u20138.","journal-title":"Epidemiol Infect"},{"issue":"9","key":"4451_CR3","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/hepr.13417","volume":"49","author":"J Tanaka","year":"2019","unstructured":"Tanaka J, Akita T, Ko K, Miura Y, Satake M, Epidemiological research group on viral hepatitis and its long -term course MoH, labour and welfare of Japan. Countermeasures against viral hepatitis B and C in Japan: an epidemiological point of view. Hepatol Res. 2019;49(9):990\u20131002.","journal-title":"Hepatol Res"},{"key":"4451_CR4","unstructured":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C.: http:\/\/www.hcvguidelines.org. Accessed 9 Jan 2025."},{"key":"4451_CR5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/hepr.13503","volume":"50","author":"Drafting Committee for Hepatitis Management Guidelines the Japan Society of Hepatology","year":"2020","unstructured":"Drafting Committee for Hepatitis Management Guidelines the Japan Society of Hepatology. Japan society of hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res. 2020;50:791\u2013816.","journal-title":"Hepatol Res"},{"key":"4451_CR6","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AASLD Practice Guidance on","year":"2023","unstructured":"AASLD Practice Guidance on. prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922\u201365.","journal-title":"Hepatology"},{"key":"4451_CR7","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"EASL recommendations on treatment of hepatitis C","year":"2020","unstructured":"EASL recommendations on treatment of hepatitis C. Final update of the series. J Hepatol. 2020;73:1170\u2013218.","journal-title":"J Hepatol"},{"key":"4451_CR8","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1053\/j.gastro.2017.03.018","volume":"152","author":"IM Jacobson","year":"2017","unstructured":"Jacobson IM, Lim JK, Fried MW. American gastroenterological association institute clinical practice update\u2014expert review: care of patients who have achieved a sustained virologic response after antiviral therapy for chronic hepatitis C infection. Gastroenterology. 2017;152:1578\u201387.","journal-title":"Gastroenterology"},{"key":"4451_CR9","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.jhep.2020.08.006","volume":"73","author":"V Calvaruso","year":"2020","unstructured":"Calvaruso V, Crax\u00ec A. Hepatic benefits of HCV cure. J Hepatol. 2020;73:1548\u201356.","journal-title":"J Hepatol"},{"key":"4451_CR10","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.cgh.2008.08.005","volume":"6","author":"KL Andersson","year":"2008","unstructured":"Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6:1418\u201324.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4451_CR11","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43:1317\u201325.","journal-title":"Hepatology"},{"key":"4451_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.21669","volume":"46","author":"A Vallet-Pichard","year":"2007","unstructured":"Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32\u20136.","journal-title":"Hepatology"},{"key":"4451_CR13","doi-asserted-by":"crossref","unstructured":"EAftSotL EASL, (EASD) EAftSoD, (EASO) EAftSoO. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492\u2013542.","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"4451_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/hepr.12393","volume":"45","author":"N Hiramatsu","year":"2015","unstructured":"Hiramatsu N, Oze T, Takehara T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol Res. 2015;45:152\u201361.","journal-title":"Hepatol Res"},{"key":"4451_CR15","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1002\/cncr.29528","volume":"121","author":"DK Li","year":"2015","unstructured":"Li DK, Chung RT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer. 2015;121:2874\u201382.","journal-title":"Cancer"},{"issue":"8","key":"4451_CR16","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3748\/wjg.v29.i8.1243","volume":"29","author":"R Nevola","year":"2023","unstructured":"Nevola R, Ruocco R, Criscuolo L, Villani A, Alfano M, Beccia D, et al. Predictors of early and late hepatocellular carcinoma recurrence. World J Gastroenterol. 2023;29(8):1243\u201360.","journal-title":"World J Gastroenterol"},{"key":"4451_CR17","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","volume":"153","author":"F Kanwal","year":"2017","unstructured":"Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153:996-e10051.","journal-title":"Gastroenterology"},{"key":"4451_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","volume":"68","author":"GN Ioannou","year":"2018","unstructured":"Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2018;68:25\u201332.","journal-title":"J Hepatol"},{"key":"4451_CR19","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jhep.2016.10.028","volume":"66","author":"NZ Janjua","year":"2017","unstructured":"Janjua NZ, Chong M, Kuo M, Woods R, Wong J, Yoshida EM, et al. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol. 2017;66:504\u201313.","journal-title":"J Hepatol"},{"key":"4451_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/hep.30823","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology. 2020;71:44\u201355.","journal-title":"Hepatology"},{"key":"4451_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-36052-0","volume":"13","author":"T Watanabe","year":"2023","unstructured":"Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, et al. Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals. Sci Rep. 2023;13:8992.","journal-title":"Sci Rep"},{"key":"4451_CR22","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/jgh.14378","volume":"34","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka A, Kumada T, Ogawa C, Kariyama K, Morita M, Nouso K, et al. Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after direct acting antivirals: multicenter analysis. J Gastroenterol Hepatol. 2019;34:436\u201341.","journal-title":"J Gastroenterol Hepatol"},{"key":"4451_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315\u201374.","journal-title":"J Hepatol"},{"key":"4451_CR24","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00535-021-01796-x","volume":"56","author":"K Tokushige","year":"2021","unstructured":"Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020. J Gastroenterol. 2021;56:951\u201363.","journal-title":"J Gastroenterol"},{"key":"4451_CR25","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","volume":"157","author":"GN Ioannou","year":"2019","unstructured":"Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, et al. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology. 2019;157:1264-78.e4.","journal-title":"Gastroenterology."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04451-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04451-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04451-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T14:46:13Z","timestamp":1764168373000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04451-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4451"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04451-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the tenets of the Declaration of Helsinki. The ethical committee of Kyoto Prefectural University of Medicine and each of the participating institutions in the study approved the study. Informed consent was obtained at each facility via an opt-out method, as approved by the institutional review boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"835"}}